P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS

por Morè, S, Manieri, V M, Corvatta, L, Morsia, E, Rupoli, S, Olivieri, A, Offidani, M
Publicado 2022

P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS?

por Morsia, E., Torre, E., Tarantino, G., Svegliati Baroni, G., Goteri, G., Mancini, S., Tassoni, A., Alessandro, F., Olivieri, A., Rupoli, S.
Publicado 2022

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report

por Morsia, E, Goteri, G, Torre, E, Garvey, KB, Discepoli, G, Tassoni, A, Mancini, S, Giantomassi, F, Poloni, A, Olivieri, A, Rupoli, S
Publicado 2021

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY

por Offidani, M., Zizzo, C., Rupoli, S., Federici, I., Bossi, A., Morè, S., Manieri, V. M., Petrucci, M. T., Caravita di Toritto, T., Brunori, M., Gozzetti, A., Tordi, A., Fazio, F., Lisi, C., Morsia, E., Corvatta, L., Olivieri, A., Duro, G.
Publicado 2022